Paratek Pharmaceuticals, Inc. (PRTK) Analysts See $-0.95 EPS as of May, 3

April 16, 2018 - By Matthew Medley

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Corporate Logo
Big Money Sentiment decreased to 0.91 in Q4 2017. It has change of 0.63, from 2017Q3’s 1.54. The ratio dived due to Paratek Pharmaceuticals, Inc. positioning: 25 sold and 29 reduced. 12 funds amassed stakes and 37 increased stakes. Investors holded 20.11 million in 2017Q3 but now own 19.34 million shares or 3.86% less.
Abingworth Llp invested in 1.04 million shs or 13.5% of the stock. Rainier Inv Mngmt Ltd Co accumulated 76,490 shs or 0.58% of the stock. Cadence Mgmt Lc has 49,328 shs for 0.06% of their capital. Swiss Bancorporation has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Highland Cap Mgmt Ltd Partnership has invested 0.19% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Art Advsr Lc reported 16,537 shs stake. 70,422 were reported by Suffolk Management Limited. Royal National Bank Of Canada stated it has 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Fincl Bank Of Montreal Can owns 65 shs. Millennium Mngmt Limited Com, a New York-based fund reported 295,622 shs. Fortress Invest Group Inc Ltd Llc reported 0.2% stake. Lpl Ltd Liability Corp holds 44,575 shs. 8,135 were reported by Metropolitan Life Insurance Ny. Falcon Point Capital Ltd Liability Corporation owns 113,415 shs. Baupost Ltd Com Ma accumulated 2.39M shs.

Earnings report for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is anticipated On May, 3., RTT reports. Analysts predict $-0.95 earnings per share, which is $0.19 up or 16.67 % from 2017’s $-1.14 earnings per share. Wall Street predicts 21.79 % negative EPS growth as of May, 3. PRTK reached $13.9 on during the last trading session after $0.25 change.Currently Paratek Pharmaceuticals, Inc. is downtrending after 26.88% change in last April 16, 2017. PRTK has 352,397 shares volume. PRTK underperformed by 38.43% the S&P 500.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Coverage

Total analysts of 5 have positions in Paratek Pharmaceuticals (NASDAQ:PRTK) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 24, 2017 according to StockzIntelligence Inc Paratek Pharmaceuticals has 6 analyst reports. On Thursday, March 1 Cantor Fitzgerald maintained the shares of PRTK in report with “Buy” rating. The company rating was maintained by Cantor Fitzgerald on Wednesday, November 8. On Friday, March 2 H.C. Wainwright maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) rating. H.C. Wainwright has “Buy” rating and $55 target. On Friday, March 2 the stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Outperform” rating by Raymond James. On Tuesday, October 24 the firm earned “Buy” rating by Robert W. Baird.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States.The firm is valued at $437.06 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea.Last it reported negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: